# The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients

> **NCT02134899** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 3 (actual)

## Conditions studied

- Autosomal Dominant Polycystic Kidney Disease

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Calcineurin inhibitors maintenance

## Key facts

- **NCT ID:** NCT02134899
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-14
- **Primary completion:** 2017-11-11
- **Final completion:** 2017-11-11
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2018-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02134899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02134899, "The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02134899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*